1
|
Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurologia 2024; 39:340-344. [PMID: 38616061 DOI: 10.1016/j.nrleng.2021.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 08/04/2021] [Indexed: 04/16/2024] Open
Abstract
BACKGROUND AND PURPOSE The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life. METHODS We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs. RESULTS Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years±8.43 and H&Y stage was 3 [2-4]. Mean dose of levodopa used was 703.75mg±233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation. CONCLUSIONS Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.
Collapse
Affiliation(s)
- P Pérez-Torre
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain.
| | - J L López-Sendón
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - V Mañanes Barral
- Neuropsychology, Movement Disorders Unit, Neurology Department, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain
| | - I Parees
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - S Fanjul-Arbós
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - E Monreal
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - A Alonso-Canovas
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | | |
Collapse
|
2
|
Morales-Casado MI, García-Meléndez DD, Diezma-Martín A, López-Ariztegui N. Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit. Rev Neurol 2023; 77:S1-S7. [PMID: 37882094 PMCID: PMC10831716 DOI: 10.33588/rn.77s03.2023212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Indexed: 10/27/2023]
Abstract
INTRODUCTION The management of motor fluctuations in Parkinson's disease (PD) can be challenging, and current therapeutic options include the use of monoamine oxidase B inhibitors (MAO-B inhibitors), among others. The aim of this study was to evaluate the effectiveness and safety of safinamide in the clinical practice carried out in the Toledo Movement Disorders Unit. PATIENTS AND METHODS This is a retrospective study in which data were collected at baseline and at six months from PD patients who were started on safinamide as an add-on therapy with a stable dose of levodopa in line with standard clinical practice. An analysis was performed by subgroups: patients who were given low-dose safinamide and patients who previously received rasagiline. RESULTS Ninety patients (47 previously received rasagiline) completed the six-month follow-up. A statistically significant decrease in morning akinesia, nocturnal akinesia, wearing off, unpredictable off phenomenon and Unified Parkinson's Disease Rating Scale-III was observed both in those who previously received rasagiline and in those treated with low doses of safinamide. No variation was found in the dyskinesias. The adverse events described were mild, with generalised weakness, dizziness, nausea, headache and alopecia. CONCLUSIONS Safinamide has been shown to be effective and safe in improving motor fluctuations, motor symptoms and the subjective perception of disease severity in PD patients previously receiving rasagiline and in those receiving low-dose safinamide, all of which is accompanied by a good safety profile.
Collapse
Affiliation(s)
| | | | - A Diezma-Martín
- Complejo Hospitalario Universitario de Toledo, Toledo, España
| | | |
Collapse
|
3
|
Jost ST, Kaldenbach MA, Antonini A, Martinez-Martin P, Timmermann L, Odin P, Katzenschlager R, Borgohain R, Fasano A, Stocchi F, Hattori N, Kukkle PL, Rodríguez-Violante M, Falup-Pecurariu C, Schade S, Petry-Schmelzer JN, Metta V, Weintraub D, Deuschl G, Espay AJ, Tan EK, Bhidayasiri R, Fung VSC, Cardoso F, Trenkwalder C, Jenner P, Ray Chaudhuri K, Dafsari HS. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Mov Disord 2023. [PMID: 37147135 DOI: 10.1002/mds.29410] [Citation(s) in RCA: 39] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/07/2023] [Accepted: 03/29/2023] [Indexed: 05/07/2023] Open
Abstract
BACKGROUND To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. OBJECTIVES To update LED conversion formulae based on a systematic review. METHODS The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. RESULTS The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. CONCLUSIONS The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Stefanie T Jost
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Marie-Ann Kaldenbach
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Angelo Antonini
- Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy
| | - Pablo Martinez-Martin
- Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain
| | - Lars Timmermann
- Department of Neurology, University Hospital Giessen and Marburg, Marburg, Germany
| | - Per Odin
- Division of Neurology, Lund University, Lund, Sweden
- Department of Neurology, Skåne University Hospital, Lund, Sweden
| | - Regina Katzenschlager
- Department of Neurology, Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders at Klinik Donaustadt, Vienna, Austria
| | - Rupam Borgohain
- Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India
| | - Alfonso Fasano
- Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital-University Health Network (UHN), Toronto, Ontario, Canada
- Division of Neurology, University of Toronto, Toronto, Ontario, Canada
- Krembil Research Institute, Toronto, Ontario, Canada
- Department of Parkinson's Disease & Movement Disorders Rehabilitation, Moriggia-Pelascini Hospital-Gravedona ed Uniti, Como, Italy
| | - Fabrizio Stocchi
- University and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Prashanth Lingappa Kukkle
- Center for Parkinson's Disease and Movement Disorders, Manipal Hospital, Bangalore, India
- Parkinson's Disease and Movement Disorders Clinic, Bangalore, India
| | - Mayela Rodríguez-Violante
- Insituto Nacional de Neurologia y Neurocirugia, Movement Disorders Clinic, Mexico City, Mexico
- Movement Disorder Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
| | - Cristian Falup-Pecurariu
- Department of Neurology, Faculty of Medicine, Transilvania University of Brașov, Brașov, Romania
- Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania
| | - Sebastian Schade
- Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen, Germany
| | - Jan Niklas Petry-Schmelzer
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Vinod Metta
- Parkinson Foundation International Centre of Excellence, King's College Hospital, London, United Kingdom
- Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Daniel Weintraub
- Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Parkinson's Disease Research, Education and Clinical Center (PADRECC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
| | - Guenther Deuschl
- Department of Neurology, University Hospital Schleswig-Holstein (UKSH), Christian-Albrechts-University Kiel, Kiel, Germany
| | - Alberto J Espay
- University of Cincinnati Gardner Neuroscience Institute, Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA
| | - Eng-King Tan
- Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore, Singapore
- Neuroscience and Behavioral Disorders (NBD) Department, Duke-NUS Medical School, Singapore, Singapore
| | - Roongroj Bhidayasiri
- Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- The Academy of Science, The Royal Society of Thailand, Bangkok, Thailand
| | - Victor S C Fung
- Movement Disorder Unit, Department of Neurology, Westmead Hospital, Westmead, Australia
| | - Francisco Cardoso
- Movement Disorders Unit, Internal Medicine Department, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Claudia Trenkwalder
- Paracelsus-Elena-Klinik, Kassel, Germany
- Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany
| | - Peter Jenner
- Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - K Ray Chaudhuri
- Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania
- Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen, Germany
- NIHR Mental Health Biomedical Research Centre and Dementia Biomedical Research Unit, South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom
| | - Haidar S Dafsari
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| |
Collapse
|
4
|
Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review. Brain Sci 2023; 13:brainsci13020276. [PMID: 36831820 PMCID: PMC9954438 DOI: 10.3390/brainsci13020276] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 01/31/2023] [Accepted: 02/02/2023] [Indexed: 02/10/2023] Open
Abstract
Parkinson's disease (PD) is a complex disease, and the treatment is focused on the patient's clinical symptoms. Levodopa continues to be the most effective drug for symptomatic PD treatment. However, chronic levodopa treatment is associated with the development of motor complications in most patients. Add-on therapeutic drugs, such as dopamine agonists and monoamine oxidase B (MAO-B) inhibitors, for example, safinamide and rasagiline, may be a desirable addition to continuously increase the levodopa dose for the optimization of motor control in PD. The scientific literature shows that safinamide significantly alleviated motor fluctuations with no increase in troublesome dyskinesia, thanks to its unique double mechanism, providing further benefits to fluctuating PD patients when compared to a placebo or other drugs. Switching from rasagiline to safinamide has been shown to improve the wearing-off phenomena, which is defined as the recurrent, predictable worsening of symptoms of parkinsonism at the end of the levodopa dose until the next dose reaches a clinical effect. In this situation, safinamide may be helpful for reducing the total daily dose of levodopa, improving the OFF time and ON time without troublesome dyskinesias, and being more effective than other MAO-B inhibitors. In this narrative review, we explore the switch from rasagiline to safinamide in patients with motor complications as a feasible and effective alternative to optimize antiparkinsonian treatment.
Collapse
|
5
|
Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. JOURNAL OF PARKINSON'S DISEASE 2022; 12:477-493. [PMID: 34957948 PMCID: PMC8925102 DOI: 10.3233/jpd-212976] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients’ motor and non-motor symptoms, reduce “OFF” time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.
Collapse
Affiliation(s)
- Yu-Yan Tan
- Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Peter Jenner
- Neurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, Faculty of Health Sciences and Medicine, King's College, London, UK
| | - Sheng-Di Chen
- Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.,Lab for Translational Research of Neurodegenerative Diseases, Institute of Immunochemistry, Shanghai Tech University, Shanghai, China
| |
Collapse
|
6
|
Pérez-Torre P, López-Sendón JL, Mañanes Barral V, Parees I, Fanjul-Arbós S, Monreal E, Alonso-Canovas A, Martínez Castrillo JC. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice. Neurologia 2021:S0213-4853(21)00129-8. [PMID: 34518027 DOI: 10.1016/j.nrl.2021.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 08/02/2021] [Accepted: 08/04/2021] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND AND PURPOSE The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life. METHODS We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs. RESULTS Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years±8.43 and H&Y stage was 3 [2-4]. Mean dose of levodopa used was 703.75mg±233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation. CONCLUSIONS Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.
Collapse
Affiliation(s)
- P Pérez-Torre
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain.
| | - J L López-Sendón
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - V Mañanes Barral
- Neuropsychology, Movement Disorders Unit, Neurology Department, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain
| | - I Parees
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - S Fanjul-Arbós
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - E Monreal
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | - A Alonso-Canovas
- Movement Disorders Unit, Neurology Department, Ramón y Cajal Hospital, Madrid, Spain
| | | |
Collapse
|
7
|
Bianchini E, Sforza M, Rinaldi D, Alborghetti M, De Carolis L, Della Gatta F, Pontieri FE. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. Neurol Res 2021; 43:950-954. [PMID: 34142645 DOI: 10.1080/01616412.2021.1942408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Besides the inhibition of monoamine-oxidase-B, high-dose safinamide (100 mg) also blocks voltage-gated Na+ and Ca++ channels and inhibits glutamate release at overactive synapses. This latter mechanism may provide further benefit to fluctuating Parkinson's disease (PD) patients compared to rasagiline. Here, we retrospectively investigated the consequences of shifting from rasagiline to high-dose safinamide in PD patients reporting symptoms of wearing-off, defined by the Wearing-Off-Questionnaire-19 (WOQ-19) score ≥3 at baseline. Seventeen PD patients were switched from rasagiline 1 mg to safinamide 100 mg because of the report of symptoms of fluctuations while under therapy with either levodopa+rasagiline or levodopa+rasagiline+dopamine agonists, or re-occurrence of fluctuations previously corrected by add-on with rasagiline. Patients were re-evaluated 4-6 months after switch. Switch to safinamide 100 mg produced benefit in 9/17 (52.9%) subjects, together with significant reduction of subjective symptoms of wearing-off. There was no report of adverse events. Findings from this retrospective, exploratory study suggest that safinamide 100 mg may produce more powerful benefit that rasagiline 1 mg as add-on to levodopa in fluctuating PD patients, possibly because of the bimodal mechanism of action of the former drug.
Collapse
Affiliation(s)
- Edoardo Bianchini
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy
| | - Michela Sforza
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy
| | - Domiziana Rinaldi
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy
| | - Marika Alborghetti
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy.,Dipartimento di Neurologia Clinica e Comportamentale, Fondazione Santa Lucia, IRCCS, Rome, Italy
| | - Lanfranco De Carolis
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy
| | - Francesco Della Gatta
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy
| | - Francesco E Pontieri
- Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, "Sapienza" Università di Roma, Rome, Italy.,Dipartimento di Neurologia Clinica e Comportamentale, Fondazione Santa Lucia, IRCCS, Rome, Italy
| |
Collapse
|
8
|
Gómez-López A, Sánchez-Sánchez A, Natera-Villalba E, Ros-Castelló V, Beltrán-Corbellini Á, Fanjul-Arbós S, Pareés Moreno I, López-Sendon Moreno JL, Martínez Castrillo JC, Alonso-Canovas A. SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease. Brain Sci 2021; 11:brainsci11010057. [PMID: 33418858 PMCID: PMC7825064 DOI: 10.3390/brainsci11010057] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 12/22/2020] [Accepted: 01/04/2021] [Indexed: 01/17/2023] Open
Abstract
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD.
Collapse
Affiliation(s)
- Ana Gómez-López
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Correspondence:
| | - Arantxa Sánchez-Sánchez
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
| | - Elena Natera-Villalba
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
| | - Victoria Ros-Castelló
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
| | - Álvaro Beltrán-Corbellini
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
| | - Samira Fanjul-Arbós
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
| | - Isabel Pareés Moreno
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
| | - José Luis López-Sendon Moreno
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
| | - Juan Carlos Martínez Castrillo
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
| | - Araceli Alonso-Canovas
- Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain; (A.S.-S.); (E.N.-V.); (V.R.-C.); (Á.B.-C.); (S.F.-A.); (I.P.M.); (J.L.L.-S.M.); (J.C.M.C.); (A.A.-C.)
- Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
| |
Collapse
|
9
|
Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. Brain Sci. 2020, 10, 176. Brain Sci 2020; 10:brainsci10050313. [PMID: 32455904 PMCID: PMC7288153 DOI: 10.3390/brainsci10050313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 05/15/2020] [Indexed: 11/17/2022] Open
|